当前位置:
X-MOL 学术
›
Regen. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib.
Regenerative Therapy ( IF 4.3 ) Pub Date : 2020-01-14 , DOI: 10.1016/j.reth.2019.11.003 Hao Zhang 1, 1, 2, 3 , Yongxian Hu 1, 1, 2, 3 , Alex H Chang 1, 2, 3 , He Huang 1, 3
中文翻译:
嵌合抗原受体T细胞疗法随后达沙替尼成功治疗T315I BCR-ABL突变的淋巴母细胞期慢性髓样白血病。
更新日期:2020-01-14
Regenerative Therapy ( IF 4.3 ) Pub Date : 2020-01-14 , DOI: 10.1016/j.reth.2019.11.003 Hao Zhang 1, 1, 2, 3 , Yongxian Hu 1, 1, 2, 3 , Alex H Chang 1, 2, 3 , He Huang 1, 3
Affiliation
中文翻译:
嵌合抗原受体T细胞疗法随后达沙替尼成功治疗T315I BCR-ABL突变的淋巴母细胞期慢性髓样白血病。